TY - JOUR T1 - Patients' perceptions and patient-reported outcomes in progressive-fibrosing interstitial lung diseases JF - European Respiratory Review JO - EUROPEAN RESPIRATORY REVIEW DO - 10.1183/16000617.0075-2018 VL - 27 IS - 150 SP - 180075 AU - Jeffrey J. Swigris AU - Kevin K. Brown AU - Rayid Abdulqawi AU - Ketan Buch AU - Daniel F. Dilling AU - Dirk Koschel AU - Krishna Thavarajah AU - Rade Tomic AU - Yoshikazu Inoue Y1 - 2018/12/31 UR - http://err.ersjournals.com/content/27/150/180075.abstract N2 - The effects of interstitial lung disease (ILD) create a significant burden on patients, unsettling almost every domain of their lives, disrupting their physical and emotional well-being and impairing their quality of life (QoL). Because many ILDs are incurable, and there are limited reliably-effective, life-prolonging treatment options available, the focus of many therapeutic interventions has been on improving or maintaining how patients with ILD feel and function, and by extension, their QoL. Such patient-centred outcomes are best assessed by patients themselves through tools that capture their perceptions, which inherently incorporate their values and judgements. These patient-reported outcome measures (PROs) can be used to assess an array of constructs affected by a disease or the interventions implemented to treat it. Here, we review the impact of ILD that may present with a progressive-fibrosing phenotype on patients' lives and examine how PROs have been used to measure that impact and the effectiveness of therapeutic interventions.Improving patient quality of life and functional status is an important aim of research and development in ILDs with a progressive phenotype. Measures of patients' perceptions and patient-reported outcomes will be required to understand our interventions. http://ow.ly/neQu30mCS89 ER -